There are almost forty (40) companies that research the treatment of mental illnesses based on the use of one or more of ten (10) different psychedelic compound-based substances (read 10 Psychedelic Substances And The 36 Companies Researching Them). The munKNEE Psychedelic Drug Stocks Index tracks the performance of the six (6) largest such psychedelic stocks by market capitalization and below are their performances this week and YTD:

1. GH Research (GHRS): UP 10.1% this week; UP 5.1% YTD
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
2. Mind Medicine (MNMD): UP 9.5% this week; UP 73.9% YTD 
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
3. Cybin (CYBN): DOWN 4.5% this week; UP 44.8% YTD
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches, and treatment regimens for psychiatric disorders.
4. Atai (ATAI): DOWN 6.4% this week; DOWN 32.2% YTD
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
5. Compass Pathways (CMPS): DOWN 7.9% this week; UP 21.3% YTD
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
6. Seelos (SEEL): DOWN 13.1% this week; UP 12.3% YTD
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.

In total, the Index value was unchanged this week so it remains UP 12.8% YTD.

More By This Author:

Canadian Cannabis LPs: CGC's Plunge Drags Category Down
Canopy Q3: Revenue -14%, Net Loss +15%; To Cut Jobs By ~60%
Aurora Q2 Financials: Net Revenue +25%, Net Profit -30%, Adj. EBITDA Turned Positive